A Study to Examine the Effects of Exenatide Once-Weekly Injection on Glucose Control and Safety in Asian Subjects

NCT00917267 · Completed

Last updated 2026-05-28

This clinical trial tested the effects of a once-weekly injection of exenatide on blood sugar control and safety in Asian adults with type 2 diabetes.

Status Completed The study has finished.

Phase Phase 3 Confirms effectiveness in a large group before approval.

Type Interventional (clinical trial)

Design Randomized, open-label (no blinding) treatment study

Participants 691 people

Who can join Ages 20+ · all sexes

Timeline Started 2009-07 · est. completion 2011-04

Where 42 sites · China, India, Japan, South Korea, Taiwan

What this study is testing ClinicalTrials.gov NCT00917267 ↗

Description as written by the study sponsor.

Previous studies have suggested that a once-weekly formulation of exenatide may provide sustained glycemic control. These previous studies of exenatide once weekly have been conducted in non-Asian populations, so this study has been developed to support the local regulatory requirements of China, Korea, Japan, India, and Taiwan.

Treatments tested

exenatide once weekly Drug

2.0mg subcutaneous injection, once a week
exenatide twice daily also known as Byetta Drug

5mcg subcutaneous injection twice a day (4 weeks), 10mcg subcutaneous injection twice a day (22 weeks)

Main thing measured	Change in HbA1c From Baseline to Week 26.
Sponsor	AstraZeneca
Conditions studied	Type 2 Diabetes Mellitus
GLP-1 drugs	exenatide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT00917267 ↗